KOL tiering is the practice of ranking key opinion leaders (KOLs) into groups usually Tier 1, Tier 2, and Tier 3 based on their scientific influence, so medical affairs and commercial teams can match the intensity of engagement to how much impact each KOL actually has.
KOL tiering is how pharmaceutical and medical device companies sort key opinion leaders into ranked groups based on influence, rather than treating every KOL relationship the same way. A KOL with global publication reach and frequent guideline authorship gets a different engagement plan than an emerging voice with local, single-region influence — tiering is the framework that makes that distinction explicit and repeatable across a medical affairs team.
Tiering comes after KOL identification — first you find the right experts, then you rank them. Without that second step, engagement tends to default to whoever's easiest to reach, not whoever has the most influence. That's the practical problem tiering solves.
Two forces drive the practice.
Resource allocation. MSL teams typically can't give equal attention to every KOL in a therapeutic area. Tiering lets a team concentrate its scarcest resources — Chief Medical Officer or Head of Medical involvement, early advisory board seats, clinical trial or publication collaboration — on the KOLs whose influence justifies it, while maintaining lighter-touch relationships with everyone else.
Consistency and compliance. When tiers rest on documented criteria rather than personal relationships, engagement decisions become easier to justify internally. The PhRMA Code on Interactions with Health Care Professionals points the same way: it says decisions about selecting health care professionals as consultants or speakers should rest on defined criteria such as medical expertise, reputation, and therapeutic-area experience — and that compensation should reflect fair market value, not the volume or value of business that professional generates.
Most medical affairs teams use a three-tier structure, though exact labels and cutoffs vary by company and therapeutic area.
Tiering models differ by company, but the criteria that show up consistently include:
One input that's often assumed to belong on this list but usually doesn't: prescribing volume. Most medical affairs-led tiering frameworks treat scientific and clinical influence as the primary basis for a tier, with prescribing volume as a secondary signal at most — a high-volume prescriber isn't automatically a thought leader, and a lower-volume researcher with guideline authorship can outrank them. There is a compliance reason for that as well as a strategic one: the PhRMA Code states that consulting and speaking arrangements should be neither inducements nor rewards for prescribing. A tiering model built on script data invites exactly the inference the Code warns against. For engagement planning — which tier gets a CMO meeting, an advisory board seat, a co-authorship pitch — scientific influence is the criterion that holds up.
No single criterion determines a tier on its own — it's the combination that produces a defensible ranking.
Four terms, constantly used interchangeably, describing four different jobs. The quickest way to keep them straight is the question each one answers.
In practice these run in sequence, and the order matters. Identification without mapping gives you a list with no sense of how influence travels through it — a moderately published KOL sitting at the centre of a referral network can matter more than a heavily published one working in isolation. Most medical affairs teams then segment before they tier: understand what kind of value a KOL brings first, then rank within each segment to set engagement intensity.
Tier assignment should drive concrete differences in how a team engages, not just an internal label:
Reviewing tier assignments on a set cadence — many teams do this annually or per launch cycle — matters because influence shifts. A Tier 3 KOL who publishes a high-impact study or takes on a guideline-committee role can move up quickly, and tiering models that aren't revisited miss that. A documented KOL engagement planning framework makes that review cadence easier to keep on schedule.
KOL tiering is only as reliable as the data underneath it. Publication activity, engagement history, advisory board participation, interaction outcomes — when those sit in scattered spreadsheets and individual MSLs' notes, tier assignments end up reflecting whoever knows a given KOL best rather than documented influence. TikaMSL's KOL management module centralises that layer — KOL relationship tracking, engagement planning, insight capture and interaction outcomes in one system — so every MSL is working from the same record when tiers are set and reviewed.
See how TikaMSL keeps KOL engagement history, insights and interaction outcomes in one place — so tier assignments rest on the same record every MSL works from.
Tier 1 KOLs typically have national or global influence — high publication output, guideline involvement, and frequent speaking engagements — while Tier 2 KOLs have similar but more regionally concentrated influence, usually with a smaller publication and speaking footprint.
No. Tiering ranks KOLs by influence level (Tier 1, 2, 3). Segmentation groups KOLs by the type of value they provide, such as clinical trial leadership versus digital/social influence. Many teams use both together.
Most medical affairs teams reassess tiering annually or aligned to a product launch cycle, since a KOL's influence — new publications, guideline roles, advisory positions — can shift meaningfully within a year.
Not directly, in most medical affairs-led frameworks. Scientific and clinical influence — publications, trial involvement, guideline roles — is the primary basis for a tier; prescribing volume is treated as a secondary signal at most, since high prescribing activity doesn't necessarily reflect scientific influence. Compliance-focused tools built for fair-market-value compensation sometimes weight prescribing or claims data more heavily, but that's a different use case than engagement-strategy tiering.
At minimum: publication history, speaking and advisory engagement records, clinical trial or guideline committee involvement, and a record of the company's own interaction history with each KOL. Fragmented or outdated data is the most common reason tiering breaks down in practice.